Yup sounds like a Coli poster who ain't got no response.May as well have been a cricket. U ain’t said shyt.
Goddamn...look at these numbers.....so Covid officially back?
- Thread starter Sad Bunny
- Start date
Bboystyle
Bang Bang Packers gang!
Thekooni.com
If you don't take it we'll ostracize you and wish death on you. You better get the shot
That dumb ass shaming bullshyt does not work.
can't wait till them effects kick in.
Antivaxxers thinking theres some common life threatening effects lol
You see republicans playing catch up now trying to tell people to take covid seriously. Their anti vaxx agenda is killing their own. That and the legal mess coming their way if they don’t stop with this political Bs.
null
...
They do have a choice. It is a personal decision in many cases.
Doctor says you are an edge case are you willing to take the risk. Just like everyone else they get the risk preamble pamphlet and then make a personal decision.
You should be one of the first to take that IQ test
But it's not a reasonable choice. Some of those people very well might have a higher risk of getting a bad reaction vaccinated than getting sick from COVID. You can keep playing semantics but clearly didn't mean those people.
The word willfully implies stubbornness to the point of detriment.
newworldafro
DeeperThanRapBiggerThanHH
Hmmm.
Drip Bayless
Superstar
Whole lotta unvaccinated fools in the spliff
Thekooni.com
If you don't take it we'll ostracize you and wish death on you. You better get the shot
That dumb ass shaming bullshyt does not work.
can't wait till them effects kick in.
Side with foolish MAGA/anti-vaxxer cacs breh....
Mr Hate Coffee
Veteran
It's about to be a hot fall
Republicans switchin it up. Now you know shyt is real
All those people were 50 and older where any sustained Covid exposure is lethal....nice try with the narrative...
null
...
my point includes those people, young people, etc.
"detriment"? playing semantics?
those small percentages end up being millions of people.
those sweeping statements are the problem because vaccination is not that simple esp. for people who have other health issues.
the CDC has detailed many of the point of administration medical considerations here - Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC .
do you feel sorry for the many fall through cases? if you do then stop making invalid sweeping statements.
e,g,
People with a history of multisystem inflammatory syndrome in children (MIS-C) or adults (MIS-A)
Currently, there are no data on the safety and efficacy of COVID-19 vaccines in people with a history of multisystem inflammatory syndrome in children (MIS-C) or in adults (MIS-A). The mechanisms of MIS-C and MIS-A are not well understood but include a dysregulated immune response to SARS-CoV-2 infection. It is unclear if people with a history of MIS-C or MIS-A are at risk of recurrence of the same dysregulated immune response following reinfection with SARS-CoV-2 or in response to vaccination. These theoretical concerns should be weighed against the known risks of COVID-19 from reinfection and the benefits of protection from a COVID-19 vaccine. Children with MIS-C have high antibody titers to SARS-CoV-2external icon; however, it is unknown if this correlates with protection against reinfection and for how long protective antibody levels persist.
People with a history of MIS-C or MIS-A may choose to be vaccinated. Considerations for vaccination may include:
Currently, there are no data on the safety and efficacy of COVID-19 vaccines in people with a history of multisystem inflammatory syndrome in children (MIS-C) or in adults (MIS-A). The mechanisms of MIS-C and MIS-A are not well understood but include a dysregulated immune response to SARS-CoV-2 infection. It is unclear if people with a history of MIS-C or MIS-A are at risk of recurrence of the same dysregulated immune response following reinfection with SARS-CoV-2 or in response to vaccination. These theoretical concerns should be weighed against the known risks of COVID-19 from reinfection and the benefits of protection from a COVID-19 vaccine. Children with MIS-C have high antibody titers to SARS-CoV-2external icon; however, it is unknown if this correlates with protection against reinfection and for how long protective antibody levels persist.
People with a history of MIS-C or MIS-A may choose to be vaccinated. Considerations for vaccination may include:
- Clinical recovery from MIS-C or MIS-A, including return to normal cardiac function
- Personal risk of severe acute COVID-19 (e.g., age, underlying conditions)
- Level of COVID-19 community transmission and personal risk of reinfection
- Lack of safety data of COVID-19 vaccines following these illnesses
- Timing of any immunomodulatory therapies (ACIP’s general best practice guidelines for immunization can be consulted for more information)
People with a history of myocarditis or pericarditis
Administration of the second dose of an mRNA COVID-19 vaccine series can be considered in certain circumstances. Considerations for vaccination may include:
Administration of the second dose of an mRNA COVID-19 vaccine series can be considered in certain circumstances. Considerations for vaccination may include:
- Personal risk of severe acute COVID-19 (e.g., age, underlying conditions)
- Level of COVID-19 community transmission and personal risk of infection
- Additional data on the risk of myocarditis or pericarditis following an occurrence of either condition after the first dose of an mRNA COVID-19 vaccine
- Additional data on the long-term outcomes of myocarditis or pericarditis that occurred after receipt of an mRNA COVID-19 vaccine
- Timing of any immunomodulatory therapies; ACIP’s general best practice guidelines for immunization can be consulted for more information
Immunocompromised people
However, data suggest immune response to COVID-19 vaccination might be reduced in some immunocompromised people including, but not limited to, people receiving chemotherapy for cancer, people with hematologic cancers such as chronic lymphocytic leukemia, people receiving stem cells or organ transplants, people receiving hemodialysis, and people using certain medications that might blunt the immune response to vaccination (e.g., mycophenolate, rituximab, azathioprine, anti-CD20 monoclonal antibodies, Bruton tyrosine kinase inhibitors).
People who are immunocompromised should be counseled about the potential for reduced immune responses to COVID-19 vaccines and the need to continue to follow current prevention measures (including wearing a mask, staying 6 feet apart from others they don’t live with, and avoiding crowds and poorly ventilated indoor spaces) to protect themselves against COVID-19 until advised otherwise by their healthcare provider. Close contacts of immunocompromised people should also be encouraged to be vaccinated against COVID-19 to help protect these people.
The safety, efficacy and benefit of additional doses of COVID-19 vaccines in immunocompromised persons continues to be evaluated. Clinical guidance for this population will be updated pending any amendments to the Emergency Use Authorizations
However, data suggest immune response to COVID-19 vaccination might be reduced in some immunocompromised people including, but not limited to, people receiving chemotherapy for cancer, people with hematologic cancers such as chronic lymphocytic leukemia, people receiving stem cells or organ transplants, people receiving hemodialysis, and people using certain medications that might blunt the immune response to vaccination (e.g., mycophenolate, rituximab, azathioprine, anti-CD20 monoclonal antibodies, Bruton tyrosine kinase inhibitors).
People who are immunocompromised should be counseled about the potential for reduced immune responses to COVID-19 vaccines and the need to continue to follow current prevention measures (including wearing a mask, staying 6 feet apart from others they don’t live with, and avoiding crowds and poorly ventilated indoor spaces) to protect themselves against COVID-19 until advised otherwise by their healthcare provider. Close contacts of immunocompromised people should also be encouraged to be vaccinated against COVID-19 to help protect these people.
The safety, efficacy and benefit of additional doses of COVID-19 vaccines in immunocompromised persons continues to be evaluated. Clinical guidance for this population will be updated pending any amendments to the Emergency Use Authorizations
Contraindications
CDC considers a history of the following to be a contraindication to vaccination with COVID-19 vaccines:
CDC considers a history of the following to be a contraindication to vaccination with COVID-19 vaccines:
- Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine
- Immediate allergic reaction of any severity to a previous dose or known (diagnosed) allergy to a component of the vaccine
Precautions
People with a contraindication to one type of the currently authorized COVID-19 vaccines (e.g., mRNA) have a precaution to the other (e.g., Janssen viral vector). However, because of potential cross-reactive hypersensitivity between ingredients in mRNA and Janssen COVID-19 vaccines, consultation with an allergist-immunologist should be considered to help determine if the patient can safely receive vaccination. Healthcare professionals and health departments may also request a consultation from the Clinical Immunization Safety Assessment COVIDvax project. Vaccination of these individuals should only be undertaken in an appropriate setting under the supervision of a healthcare professional experienced in the management of severe allergic reactions.
People with a contraindication to one type of the currently authorized COVID-19 vaccines (e.g., mRNA) have a precaution to the other (e.g., Janssen viral vector). However, because of potential cross-reactive hypersensitivity between ingredients in mRNA and Janssen COVID-19 vaccines, consultation with an allergist-immunologist should be considered to help determine if the patient can safely receive vaccination. Healthcare professionals and health departments may also request a consultation from the Clinical Immunization Safety Assessment COVIDvax project. Vaccination of these individuals should only be undertaken in an appropriate setting under the supervision of a healthcare professional experienced in the management of severe allergic reactions.
- People with a contraindication to mRNA COVID-19 vaccines (including due to a known PEG allergy): Consideration may be given to vaccination with Janssen COVID-19 vaccine. People who have received one mRNA COVID-19 vaccine dose but for whom the second dose is contraindicated should wait at least 28 days after the mRNA vaccine dose to receive Janssen COVID-19 vaccine.
- People with a contraindication to Janssen COVID-19 vaccine (including due to a known polysorbate allergy): Consideration may be given to mRNA COVID-19 vaccination. Of note, polysorbate allergy is no longer a contraindication to mRNA COVID-19 vaccination, it is a precaution.
"if" ...
and then you have personal risk assessment based on things like the UK (for example) coming to a different risk assessment for vaccination of youth (12+) than the USA.
note: 24% of the USA is under 18 years old.
"U.K. opts not to vaccinate most under-18s against COVID-19"
U.K. opts not to vaccinate most under-18s against COVID-19
British ministers decide against mass vaccination for teens - The Telegraph
"CDC recommends everyone 12 years and older should get a COVID-19 vaccination to help protect against COVID-19."
COVID-19 Vaccination
null
...
Kornball The Conqueror
Superstar
Right wingers thanos snapping themselves out of the voting pop